Bionano Genomics, Inc: insider trades · United States · SEC (Form 4)

About Bionano Genomics, Inc

Bionano Genomics, Inc. is a U.S.-based biotechnology company listed on the NASDAQ under ticker BNGO, with operations centered in the United States. Headquartered in San Diego, California, the company develops genome-analysis solutions built around optical genome mapping (OGM), a technology designed to detect large structural variants and complex genomic rearrangements that can be difficult to resolve with conventional sequencing methods. Founded in 2003, Bionano has evolved into a specialized genomics tools provider focused on research and clinical-adjacent applications. ([fintel.io](https://fintel.io/doc/sec-bionano-genomics-inc-1411690-10k-2024-march-05-19787-9392?utm_source=openai)) Its core commercial platform is Saphyr, alongside Stratys, supported by consumables, software, and workflow products. The business model is based on instrument placements followed by recurring revenue from flowcells, reagents, and analytics software, which gives the company a classic installed-base monetization profile. Bionano also offers nucleic acid purification solutions and genomics software through acquired assets such as BioDiscovery, broadening its product portfolio beyond the OGM instrument itself. In practical terms, the company targets laboratories in cytogenomics, translational research, and oncology, with particular emphasis on rare disease, hematologic malignancy, and structural-variant analysis workflows. ([stocktitan.net](https://www.stocktitan.net/sec-filings/BNGO/?utm_source=openai)) From a competitive standpoint, Bionano occupies a niche position in structural genomics. That specialization is a key differentiator versus broader molecular diagnostics and next-generation sequencing players, but it also means the company depends on long adoption cycles, clinical validation, reimbursement progress, and sustained laboratory demand. Public disclosures indicate a growing installed base: management reported an estimated 371 OGM systems at year-end 2024, compared with 326 at year-end 2023, and later sources tied to 2025 SEC reporting referenced 387 systems as of December 31, 2025. That trajectory suggests continued commercialization, even if the company remains in a highly competitive and execution-sensitive stage. ([ir.bionano.com](https://ir.bionano.com/news-releases/news-release-details/bionano-reports-preliminary-fourth-quarter-and-full-year-2024/?utm_source=openai)) Recent milestones have included preliminary full-year 2024 and 2025 results, continued product and scientific presentations, and messaging around broader adoption of OGM in both U.S. and international markets. Bionano has also highlighted clinical and reimbursement progress tied to cytogenomic use cases, which is an important catalyst for future demand if adoption continues to broaden. For international equity investors, the stock represents a U.S.-listed small-cap healthcare name on NASDAQ with a high-risk/high-upside profile: the thesis depends on the company converting scientific differentiation into durable commercial penetration and recurring revenue growth. ([ir.bionanogenomics.com](https://ir.bionanogenomics.com/news-releases/news-release-details/bionano-reports-third-quarter-2024-results-and-highlights-recent/?utm_source=openai))